COPD PPT | Medicine powerpoint lecture

| March 24, 2011 | 0 Comments


PowerPoint lecture slide

Size: 746 kb


Copy and visit the following link to download


Contents of PPT File excluding images. Download this file to see all contents




•      A 55 year old male presents to the office with worsening shortness of breath over the past 6 months.  He has a morning cough productive of thick white sputum.  He denies any chest pain.  His weight has been stable.  He has a 45 pack year smoking history and continues to smoke ½ pack per day.  HeCOPDm3 2006 COPD PPT | Medicine powerpoint lecture drinks several beers on the weekends.  He is divorced and works as an engineer.  What of the following tests should you order to work up his dyspnea?

•      Pulmonary Function Tests including DLCO

•      Chest x-ray

•      Spiral CT to rule out chronic thromboembolic disease

•      High-resolution CT to evaluate for interstitial fibrosis

•      Methacholine challenge

•      Allergy Skin Testing

•      Pre- and Post-Bronchodilator spirometry

•      Arterial blood gas

•      6 minute walk


•      The severity of disease in COPD is assessed by _________.  The classification system is called ________.

•      Disease severity ________ (is or is NOT) associated with mortality.

Other tests

•      Bronchodilator reversibility

–    Helpful to rule out a diagnosis of asthma, to establish a patient’s best attainable lung function, to gauge a patient’s prognosis, and to guide treatment decisions

–    Even patients who do not show a significant FEV1 response to a short-acting bronchodilator test may benefit symptomatically

•      CXR-seldom diagnostic unless obvious bullous disease is present but it is valuable in excluding alternative diagnosis

•      ABG-should be measured in patients with FEV1<40% predicted or with cor pulmonale

•      Alpha-1 antitrypsin deficiency:  in patients who develop COPD at a young age or who have a family history

COPD Definition
Fill in the blanks

•      Disease state characterized by ____________ that is not fully __________.  The _______________  is usually both progressive and associated with an abnormal inflammatory response of the lungs to _______________.

COPD Definition

•      Disease state characterized by airflow limitation that is not fully reversible.  The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases.

•      Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease www.goldcopd.com

Pathology of COPD
Fill in the boxes


•      What is the single most effective intervention to stop the progression of COPD in this patient?

•      How would you do this?  Be specific.

Smoking Cessation

•      Single most effective (and cost effective) intervention to reduce the risk of developing COPD and stop its progression

•      Brief tobacco dependence treatment is effective and every tobacco user should be offered at least this treatment at every visit to the health care provider

Strategies to Help the Patient Willing to Quit Smoking

•      1.  ASK:  Systematically identify all tobacco users at every visit.

•      2.  ADVISE:  Strongly urge all tobacco users to quit.

•      3.  ASSESS:  Determine willingness to make a quit attempt.

•      4.  ASSIST:  Aid the patient in quitting

•      5.  ARRANGE:  Schedule follow-up contact


•      Nicotine replacement reliably increases long-term smoking abstinence rates

•      Bupropion and Nortriptyline have been shown to increase long-term quit rates

•      A 61 year old female presents to the office with worsening shortness of breath.  Symptoms have been gradually worsening over the past several years.  She has a chronic cough productive of white sputum.  Patient was started on oxygen by her primary care physician last month and was referred to you for further evaluation.  Her past medical history is significant for hypertension.  She quit smoking several years ago.  She drinks one glass of wine a day.  She recently quit her job as a day care provider.  She denies any fever or chills.  Her current medications are:

•      VoSpire (Albuterol) ER 8 mg po Q 12 hours

•      Atrovent nebulizers Q 6 hours

•      Prednisone 10mg po Q day

•      Theophylline 200mg po BID

•      Inderal (Propranolol) 80 mg po BID

•      On exam, T 37.5 HR 82 R 16 BP 135/65 Sats 95% on 2L O2 by nasal cannula.  She has a mildly increased P2 on cardiac exam.  She has a prolonged expiratory phase on lung exam with scattered end-expiratory wheezes.  The rest of her exam is normal.  Her CXR is available for review.  Her pulmonary function tests are:  FVC 1.56 L 59% predicted improving to 1.9 L 72% predicted, a 22% improvement.  FEV1 0.67 36% predicted improving to 0.92 L a 37% improvement.  TLC 120% predicted.  RV 191% predicted and DLCO 38% predicted.

•      How would you rate the severity of her disease?

•      What adjustments should be made to her medical regimen?

•      Can anything be done to prolong her life?

•      Are there any non-medical options available to improve her condition?

Which of the following are objectives of COPD management?

•      Prevent disease progression

•      Improve pulmonary function tests

•      Relieve symptoms

•      Repair emphysematous lungs

•      Improve exercise tolerance

•      Improve health status

•      Decrease oxygen requirements

•      Prevent and treat exacerbations

•      Reduce mortality

•      Minimize side effects from treatment

Objectives of COPD Management

•      Prevent disease progression

•      Relieve symptoms

•      Improve exercise tolerance

•      Improve health status

•      Prevent and treat exacerbations

•      Prevent and treat complications

•      Reduce mortality

•      Minimize side effects from treatment

Monitor Disease Progression

•      COPD is a progressive disease, and a patient’s lung function can be expected to worsen over time, even with the best available care

Manage Stable COPD

•      Stepwise increase in treatment, depending on the severity of the disease.

•      Patient education improves skills, ability to cope with illness and health status.

•      None of the existing medications for COPD has been shown to modify the long-term decline in lung function.  So pharmacotherapy is used to decrease symptoms, reduce the frequency and severity of exacerbations, improve health status, and improve exercise tolerance

Manage Stable COPD: Bronchodilators

•      Bronchodilator medications are central to the symptomatic management of COPD.  They are given on an as-needed basis or on a regular basis to prevent or reduce symptoms.

–     Alleviate symptoms

–     Improve exercise tolerance

–     Improve quality of life

–     Decrease the incidence of exacerbations

–     Decrease hyperinflation

•      Inhaled therapy is preferred

Manage Stable COPD:  Bronchodilators

•      Beta2-agonists:  increase cyclic adenosine monophosphate levels and promote airway smooth-muscle relaxation

–    Short acting:  Albuterol (Proventil)

–    Long acting:  Salmeterol (Serevent)  and

Formoterol fumarate (Foradil)

•      Anticholinergics:  block muscarinic receptors

–    Short acting:  Ipratropium bromide (Atrovent)

–    Long acting:  Tiotropium bromide (Spiriva)

•      Combination:  (Combivent, DuoNeb)

Manage Stable COPD:  Bronchodilators

•      Phosphodiesterase Inhibitors:  increase intracellular cyclic adenosine monophosphate levels within airway smooth muscle

–    3rd line agent

–    Improves respiratory muscle function, stimulates the respiratory center, decreases dyspnea, and enhances activities of daily living

–    Toxic side effects:  tachyarrhythmias, nausea, vomiting, seizures

–    Monitoring should include intermittent serum level measurements:  target range 8-12mcg/mL

Inhaled Steroids (ICS) in Stable COPD

•      Glucocorticoids act at multiple points within the inflammatory cascade.

•      Regular treatment with ICS does not modify the long-term decline in FEV1.

•      Appropriate for symptomatic COPD patients with an FEV1 < 50% and repeated exacerbations (Stage III and IV).

•      ICS reduce frequency of exacerbations and improve health status (Evidence A).

•      ICS combined with long-acting 2-agonist more effective than individual components.

Steroids in Stable COPD

•      GOLD guidelines recommend a trial of 6 weeks to 3 months of ICS to identify subset of patients who may benefit.

•      Short course of oral steroids is a poor predictor of long-term response to ICS.

•      Long-term treatment with oral steroids is NOT recommended (Evidence A):

–   No evidence of long-term benefit

–   Major side effects:  skin damage, cataracts, diabetes, osteoporosis, secondary infection, psychosis, fluid retention

Other pharmacologic treatments

•       Vaccines: Influenza vaccine reduces serious illness and death in COPD patients by 50%.  Pneumococcal vaccine is recommended every 5 years although data in COPD patients is lacking.

•       Other anti-inflammatory agents:  Cromolyn, nedocromil, and leukotriene inhibitors have not been adequately tested in patients with COPD

•       Alpha-1 Antitrypsin Augmentation Therapy:  young patients with severe deficiency and established emphysema

•       Antibiotics are not recommended other than in treating infectious exacerbations (Doxycycline, amoxicillin, macrolide, fluoroquinolones)

•       Mucolytic agents:  not recommended

•       Antioxidants (N-acetylcysteine) may reduce the frequency of exacerbations

•       Antitussives:  contraindicated in stable COPD because cough is protective

•      Comprehensive pulmonary rehabilitation programs have been shown to improve all of the following EXCEPT:

•      A.  Measured FEV1

•      B.  Respiratory symptoms

•      C.  6-Minute walk test

•      D.  Need for outpatient care and inpatient hospitalizations

•      E.  Symptoms of anxiety, depression, and lack of well-being

Pulmonary Rehabilitation in Stable COPD

•      All COPD-patients benefit from exercise training programs, improving with respect to both exercise tolerance and symptoms of dyspnea and fatigue (Evidence A).

•      The minimum length of an effective rehab program is 2 months; the longer the better (Evidence B).

•      Comprehensive pulmonary rehabilitation program includes exercise training, nutrition counseling, and education.

Manage Stable COPD: Oxygen

•      The long-term administration of oxygen (> 15 hours per day) to patients with chronic respiratory failure (Stage IV) has been shown to increase survival (Evidence A).

•      Oxygen administration reduces hematocrit, pulmonary artery pressures, dyspnea, and rapid eye movement related hypoxemia during sleep.

•      Tailor prescription to patient:  source, method of delivery, duration of use, flow rate at rest, during exercise, and sleep

•      A 59 year old male presents with worsening shortness of breath.  He was diagnosed with COPD several years ago and was told to wear oxygen at home.  However, he doesn’t feel like he needs it.  He continues to exercise for several minutes a day on the treadmill and does pull-ups.  In the office, his O2 sats are 83% on room air so he is admitted to the hospital.  T 98.9  HR 103 R 24 BP 142/82  Sats 91% on 6 L oxymizer.  His weight is 144 lbs at 68 inches.  He has temporal wasting.  He has supraclavicular fullness, jugular venous distension to the jaw, a prominent P2 on cardiac exam. He has poor air movement throughout both lung fields.

•      Pulmonary function tests:  FEV1/FVC 28.6%  FEV1 0.51 L 18% predicted; FVC 1.8L 52% predicted.  With albuterol, his FVC increases to 2.07 L, a 14% improvement.  His TLC is 151% predicted.  His RV is 359% predicted.

•      How would you rate his severity of disease?

•      How should this patient be treated?

•      What (if any) bronchodilators would you use?

•      Is there any role for inhaled corticosteroids?

•      What about systemic corticosteroids?

•      Any other beneficial interventions?

True or False

•      COPD is a disease process limited to the lungs. _______

•      COPD is the only disease in which mortality rates have been rising over the past several decades.  _________

COPD is a systemic disease

•      Systemic inflammation

•      Skeletal muscle dysfunction

•      Nutritional problems

•      High prevalence of depression and anxiety

–   PRIME-MD:  1334 VA patients with COPD:  80% screened positive for depression or anxiety

–   Nicotine helps mitigate these symptoms

•      COPD is the  ___ leading cause of death in the United States.

•      A.  2nd

•      B.  4th

•      C.  6th

•      D.  10th


•      4th leading cause of death in the USA

•      In 2000, WHO estimates 2.74 million deaths worldwide from COPD

–    In 2000, more women than men died of COPD in U.S. (59,936 vs 59,118)

•      Age-adjusted death rates are rising

•      High burden of disease

–    Approx. 16 million office visits (USA, 1995)

–    500,000 hospitalizations for COPD

–    Medical expenditures ~ 15 billion dollars/yr;

–    $32 billion in direct and indirect costs in 2002

Management Stage 0:  At Risk for COPD

Management Stage I:  Mild COPD

Management of Stage II:
Moderate COPD

Management of Stage III:  Severe COPD

Management of Stage IV:
Very Severe COPD

Surgical Treatments

•      Bullectomy:  In carefully selected patients, this procedure is effective in reducing dyspnea and improving lung function (Evidence C)

•      Lung Volume Reduction Surgery

•      Lung Transplantation:  In appropriately selected patients, improves quality of life and functional capacity (Evidence C).  Criteria for referral:  FEV1<35% predicted PaO2<55-60mm Hg, PaCO2>50 mm Hg, and secondary pulmonary hypertension

Lung Volume Reduction Surgery

•      National Emphysema Treatment Trial Research Group

•      1218 patients with severe emphysema underwent pulmonary rehabilitation and were randomly assigned to undergo lung-volume reduction surgery or to receive continued medical treatment

•      Increases chance of improved exercise capacity but does not confer a survival advantage

•      Survival advantage for patients with predominantly upper-lobe emphysema and low base-line exercise capacity

•      A 70 year old male with GOLD stage III COPD  has had increased shortness of breath, chest tightness, and a cough productive of yellow sputum.  In the ER, T 98.9 HR 115 R 32 BP 120/80 Sats 89% on 2 L O2 (his home O2 requirement).  He is using accessory muscles (sternocleidomastoids) and has thoracoabdominal dyssynchrony.  He has very poor air movement bilaterally on lung exam.  The rest of his exam is unremarkable.

•      How severe is his exacerbation?

•      What lab tests/x-rays should you order?

•      How should you treat him?


•      Increased breathlessness, wheezing, chest tightness

•      Increased cough and sputum

•      Change in color and/or tenacity of sputum

–    An increase in sputum volume and purulence points to a bacterial cause

•      Nonspecific complaints:  fever, malaise, fatigue, depression, confusion

Assessment of severity of exacerbation

•      Peak flow <100 L/min or FEV1 <1.0 L indicates severe exacerbation

•      ABG

•      CXR

•      EKG

•      D-dimer, spiral CT

•      Sputum culture

Manage Exacerbations: Key Points

•      Inhaled bronchodilators (Beta2-agonists and/or anticholinergics), theophylline, and systemic, preferably oral, glucocortico-steroids are effective for the treatment of COPD exacerbations (Evidence A).

•      80% of AECB are infectious.  Environmental factors and medication nonadherence are 20%.

Manage Exacerbations: Key Points

•      Noninvasive intermittent positive pressure ventilation (NIPPV) in acute exacerbations improves blood gases and pH, reduces in-hospital mortality, decreases the need for invasive mechanical ventilation and intubation, and decreases the length of hospital stay (Evidence A).


•      Selection criteria:

–    Moderate to severe dyspnea with use of accessory muscles and paradoxical abdominal motion

–    Moderate to severe acidosis and hypercapnia

–    Respiratory frequency >25/min

•      Exclusion criteria:

–    Respiratory arrest

–    Cardiovascular instability

–    Somnolence, impaired mental status, uncooperative patient

–    High aspiration risk

–    Viscous or copious secretions

–    Recent facial or gastroesophageal surgery

–    Craniofacial trauma

–    Extreme obesity

•      He is admitted to 5500.  How should he be treated?  The nurse calls you because the patient is poorly responsive.  T 98.6 HR 125 R 16 BP 110/65 Sats 92% on 50% face mask.  Patient is barely arousable by sternal rub.  What do you want to do now?

•      Which of the following is NOT true about this patient?

•      A.  His inpatient mortality rate is 25%.

•      B.  If he survives this hospitalization, he is likely to be readmitted within 6 months.

•      C.  This is the ideal time to discuss code status with the patient’s family.

•      D.  The patient’s five year mortality is 70%.

•      Retrospective study of 57 patients with COPD admitted to the ICU with a COPD exacerbation

•      90% intubated

•      In-hospital mortality 24.5%

•      Median survival 26 months

•      Mortality rate at 5 years 69.6%

•      Chest 2005; 128:518-24

© DENTIST BD BLOG . All rights reserved.
WARNING: Any unauthorised use or reproduction of  gr.dentistbd.com content for commercial or any purposes is strictly prohibited and constitutes copyright infringement liable to legal action.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Category: Lectures, Medicine

WARNING: Any unauthorised use or reproduction of  gr.dentistbd.com content for commercial or any purposes is strictly prohibited and constitutes copyright infringement liable to legal action.